Interestingly, our current data reveals that EphB6 has a completely opposite function in T-ALL cells, since inhibition of its action through the expression of a dominant-negative mutant or by shRNA-based silencing inhibits doxorubicin-triggered apoptotic cell death and this effect is supported by the increased Akt activation. Here, EPHB6 is linked to acute lymphoblastic leukemia.